comparemela.com
Home
Live Updates
REGENXBIO Announces Completion of Dosing in the Phase I/II T
REGENXBIO Announces Completion of Dosing in the Phase I/II T
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it has completed dosing in the expanded Cohort 2 of the Phase I/II trial of RGX-111 for the...
Related Keywords
United States ,
Brazil ,
Dana Cormack ,
Chris Brinzey ,
Steve Pakola ,
Technology Platform ,
Technology Platform Licensees ,
Drug Administration ,
Nasdaq ,
Exchange Commission ,
Corporate Communications ,
Securities Exchange ,
Manufacturing Innovation Center ,
Chief Medical Officer ,
Mucopolysaccharidosis Type ,
Chief Executive Officer ,
Fast Track ,
Platform Licensees ,
Securities Act ,
Securities Exchange Act ,
Financial Condition ,
Regenxbio Inc ,